Changes in Breast Cancer Biomarkers from Primary to Recurrence
Author Information
Author(s): Alastair M Thompson, Lee B Jordan, Philip Quinlan, Elizabeth Anderson, Anthony Skene, John A Dewar, Colin A Purdie
Primary Institution: Ninewells Hospital and Medical School, Dundee, UK
Hypothesis
Does the receptor status of estrogen, progesterone, and HER2 change between primary and recurrent breast cancer?
Conclusion
The study confirms that receptor status changes in breast cancer can significantly influence treatment decisions for patients with recurrence.
Supporting Evidence
- A switch in receptor status was identified for ER in 10.2% of patients.
- PR status changed in 24.8% of patients.
- HER2 status changed in 2.9% of patients.
- The switch in receptor status led to a change in treatment for 17.5% of patients.
Takeaway
When women with breast cancer have a recurrence, their tumor's characteristics can change, which might mean they need different treatments.
Methodology
The study collected matched primary and recurrent breast cancer tissue samples from 205 women and analyzed them for ER, PR, and HER2 status.
Potential Biases
Potential bias due to the long duration between primary and recurrent disease and the method of tissue acquisition.
Limitations
Some patients were lost to follow-up, and there were issues with tissue availability and misdiagnosis of recurrence.
Participant Demographics
Mean age was 62.6 years, with 60.6% postmenopausal and predominantly Caucasian participants.
Statistical Information
P-Value
{"ER":0.983,"PR":0.003,"HER2":0.074}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website